Diabetes news and diabetes widget

Genaera Corporation (Nasdaq: GENR) announced that dosing of subjects has begun in study MSI-1436C-102 (Study 102), the multiple ascending dose Phase 1b study of trodusquemine (MSI-1436) in overweight and obese type 2 diabetics. MSI-1436 is a novel therapeutic for the treatment of type 2 diabetes and obesity which works centrally and peripherally to regulate insulin and leptin pathways through the highly selective inhibition of its novel target enzyme, PTP-1B.

As reported in New England Journal of medicine (Oct 30, 2008), Diamyd® preserves insulin producing beta cells best in patients recently diagnosed with the disease. Beta cell destruction is a consecutive process, eventually leading to the need for life-long treatment with insulin. Diamyd® given before clinical presentation could hence prevent the onset of the disease.

Title: Antibiotics Largest Cause of Drug-Induced Liver DamageCategory: health newscreated: 12/2/2008 2:00:00 amlast Editorial review: 12/2/2008

Title: Too Little Vitamin D Puts Heart at RiskCategory: health newscreated: 12/2/2008Last Editorial review: 12/2/2008